American pharmaceutical giant and Covid vaccine manufacturer Johnson & Johnson announced that it ended the fourth quarter of the year with unadjusted profits up to $ 4.74 billion, nearly tripled from $ 1.74 billion in the same period last year. .
Revenue also grew, up 10.8% year-on-year from $ 22.48 billion in the fourth quarter of 2020, mainly thanks to international sales of the Covid vaccine, amounting to $ 1.82 billion.
However, the turnover was less than the $ 25.29 billion expected by the consensus.
Adjusted eps came in at $ 2.13, better than the $ 2.12 per share expected by analysts.
In full 2021 Johnson & Johnson reported a turnover of $ 93.77 billion, up 13.6% year-on-year: the pharmaceutical division generated revenues of $ 52.08 billion, up 14.3 % every year. The medical equipment division grossed $ 27.06 billion in sales in 2021, up 17.9% year-on-year. The consumer products division saw revenue increase 4.1% to $ 14.63 billion.
J&J also announced that it expects an eps of between $ 10.40 and $ 10.60 this year, on revenues between $ 98.9 billion and $ 100.4 billion.
The giant also announced that its Covid vaccine will generate sales of between $ 3 billion and $ 3.5 billion in 2022.